tolerated for years, but their efficacy is relatively modest. Immunosuppressants are more effective, but their toxicity prevents long-term treatments. Numerous clinical trials investigate new molecules in order to improve the efficacy of immunomodulators and reduce the toxicity of immunosuppressants. This short review will be limited to the most promising new therapeutic approaches.
Approved Therapies

Immunomodulators
Interferons-beta
IFNβ downregulates T-cell proliferation and pro-inflammatory cytokine production. Their most evident anti-inflammatory effect concerns active brain lesions, demonstrated by a ~80-90% decrease of gadoliniumenhancing (Gd+) lesions. The clinical benefit on relapses is definitely less marked (~30%), and the long-term effect on disability progression is modest (~20%) and remains a matter of debate. Several attempts to improve IFNβ efficacy are in progress. A benefit of higher doses has been found with IFNβ 1b (500 versus 250µg) and IFNβ 1a sc (44 versus 22µg). 3 In contrast, a higher dose of IFNβ 1a im (60 versus 30µg) did not improve the benefit and led to a greater incidence of NAbs. 4 An increased formulation purity of IFNβ 1a sc is currently being tested. Preliminary data demonstrate a much lower persistence of NAbs and a three-fold reduction of adverse events. 5 A potential increased clinical benefit remains to be assessed.
Glatiramer Acetate (Copaxon ® )
GA is a mixture of four synthetic polypeptides participating in the structure of myelin basic protein (MBP), which plays a major role in the development of allergic experimental encephalomyelitis (EAE). The most likely mechanisms of action are competition with MBP in binding to the major histocompatibility complex (MHC) molecule -acting as an altered peptide ligand -and the induction of GA-reactive T regulatory cells producing brain-derived neurotrophic factor. GA exerts beneficial effects on relapse rate and disability progression at a magnitude comparable to that of IFNβ.
The first magnetic resonance imaging (MRI) studies demonstrated a reduction in Gd+ lesions by 33% -less than that with IFNβ. Tolerance is acceptable, but some patients present systemic reactions specific to GA characterised by flushing, chest pain, anxiety, dyspnoea and constriction of the throat, usually resolving within half an hour. To improve the efficacy of GA, higher doses have recently been tested (40 versus 20mg).
Preliminary data suggest that a double dose may be more effective in reducing MRI activity and relapse rate, with a similar tolerance. It has come to be accepted that MX provides an effective treatment in most acutely worsening MS patients who do not respond to IFNβ or GA. 7 The best responders to MX therapy are patients with an RR course, more than three relapses in the previous 24 months and at least one Gd+ lesion. 8 Two important issues can be addressed: the most effective and least toxic treatment regimen, and the optimal maintenance therapy. The eradication of Gd+ lesions within three months of monthly infusions versus six months after quarterly administration favours a treatment regimen combining an induction phase of three monthly infusions followed by administration every three months as a maintenance therapy.
The cardiotoxicity of MX is a major dose-limiting factor. Cumulative doses over 140mg/m 2 can lead to severe and irreversible myocardial dysfunction. However, there is a growing appreciation that cardiotoxicity can occur at lower cumulative doses. The FDA has thus recently updated its warnings and recommends a control of the left ventricular ejection fraction (LVEF) before every dose. Another concern about MX toxicity is the delayed occurrence of therapeutic-related acute leukaemia (TRAL). It is difficult to correctly appreciate the risk of TRAL, as the exact number of MS patients exposed to MX is unknown and cases of TRAL can be subject to under-reporting. According to the data from two prospective postmarketing studies 9,10 on a total of 1,311 patients, the incidence is between 0.20 and 0.25%. However, 19 sporadic cases have been reported in the literature with a worrying incidence in two centres of 2.7% (3/111 patients) 11 and 0.8% (2/250 patients). 12 
Natalizumab (Tysabri ® )
Natalizumab, an immunosuppressor acting on cell-surface ligands, is a humanised monoclonal antibody targeting the α4 integrin chain of the VLA-4 adhesion molecule involved in transendothelial cell migration of immunocompetent cells into brain parenchyma. Leukocyte and lymphocyte counts in peripheral blood remain unaltered. In contrast, all lymphocyte subtypes are significantly reduced in the cerebrospinal fluid (CSF), likely mirroring reduced brain infiltration. In RR MS patients, natalizumab reduces Gd+ lesions by 92%. 13 The benefit seems better than after administration of IFNβ or GA; this also applies to relapses (relative risk reduction (RRR) 68 versus 33%) and disability progression (RRR 42 versus ~20%). Unfortunately, two out of 1,216 patients treated with natalizumab experienced progressive multifocal leucoencephlopathy (PML) -a JC virus infection. Even though both of these patients were participating in the trial combining IFNβ and natalizumab, 14 
Experimental Therapies
FTY720 (Fingolimod ® )
Fingolimod ® converts endogenous sphingosine into its phosphate form, which is a high-affinity agonist of the sphingosine 1 (S1P1) receptor. 
BBR2778 (Pixantrone ® )
Pixantrone ® is an analogue of MX without severe cardiotoxicity. In addition, its weaker DNA-constant binding and its lower stimulation of topoisomerase II-mediated DNA alterations suggest a lower risk of TRAL. In animal experiments, pixantrone was found to be less cardiotoxic than MX, and its immunosuppressive activity on the cellular and humoral components of the immune system is the same as that of MX. This new molecule might thus be an interesting substitute for MX in MS patients, and a phase I/II trial is in progress.
Alemtuzumab (Campath-1H ® )
Alemtuzumab, a monoclonal Ab targeting the surface CD52 molecule mainly expressed on T lymphocytes and monocytes, is a potent and selective immunosuppressant of cellular immunity leading to a complete deletion of lymphocytes. Monocytes and B cells return to normal within three months, but T-cell depletion persists for up to five years. Administration of alemtuzumab early after disease onset (mean disease duration 2.7 years) not only stopped relapses but also yielded a definite reduction in disability state over two years. 17 These observations suggest that a very early suppression of the inflammatory environment likely reduces the production of microglial toxic factors and the early concomitant axonal loss. The main side effect of alemtuzumab is a cytokine-release syndrome requiring pre-treatment with corticosteroids. The development of autoimmunity after alemtuzumab administration is another concern, leading to Graves' disease in 27% of treated patients and, less frequently, to Goodpasture's syndrome.
Conclusions
The overall benefit of INFβ and GA is modest. Nevertheless, given their 18 Several experimental therapies appear promising, but the follow-up is too short to fully appreciate their long-term toxicity. ■
